Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.

ABSTRACT:

Background

Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress HER2. We have recently demonstrated that the clinically important isoform of HER2, HERΔ16, promotes therapeutically refractory breast cancer including resistance to endocrine therapy. Likewise additional breast tumor cell models of tamoxifen resistance have been developed that do not involve HER2 overexpression. However, a unifying molecular mechanism of tamoxifen resistance has remained elusive.

Results

Here we analyzed multiple cell models of tamoxifen resistance derived from MCF-7 cells to examine the influence of microRNAs (miRNAs) on tamoxifen resistance. We compared miRNA expression profiles of ta

SUBMITTER: Cittelly DM 

PROVIDER: S-EPMC3024251 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature